ATNF vs. AEZS, VINC, EDSA, SYRS, AEON, CANF, ONVO, MAAQ, CHRO, and LIXT
Should you be buying 180 Life Sciences stock or one of its competitors? The main competitors of 180 Life Sciences include Aeterna Zentaris (AEZS), Vincerx Pharma (VINC), Edesa Biotech (EDSA), Syros Pharmaceuticals (SYRS), AEON Biopharma (AEON), Can-Fite BioPharma (CANF), Organovo (ONVO), Mana Capital Acquisition (MAAQ), Chromocell Therapeutics (CHRO), and Lixte Biotechnology (LIXT). These companies are all part of the "pharmaceutical products" industry.
180 Life Sciences vs.
180 Life Sciences (NASDAQ:ATNF) and Aeterna Zentaris (NASDAQ:AEZS) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their risk, earnings, valuation, institutional ownership, community ranking, media sentiment, analyst recommendations, dividends and profitability.
Aeterna Zentaris received 417 more outperform votes than 180 Life Sciences when rated by MarketBeat users. Likewise, 59.52% of users gave Aeterna Zentaris an outperform vote while only 40.00% of users gave 180 Life Sciences an outperform vote.
180 Life Sciences has a beta of 0.13, suggesting that its stock price is 87% less volatile than the S&P 500. Comparatively, Aeterna Zentaris has a beta of 1.55, suggesting that its stock price is 55% more volatile than the S&P 500.
Aeterna Zentaris has higher revenue and earnings than 180 Life Sciences.
180 Life Sciences has a net margin of 0.00% compared to Aeterna Zentaris' net margin of -760.32%. Aeterna Zentaris' return on equity of -83.45% beat 180 Life Sciences' return on equity.
In the previous week, 180 Life Sciences had 2 more articles in the media than Aeterna Zentaris. MarketBeat recorded 2 mentions for 180 Life Sciences and 0 mentions for Aeterna Zentaris. 180 Life Sciences' average media sentiment score of 0.00 equaled Aeterna Zentaris'average media sentiment score.
4.1% of 180 Life Sciences shares are held by institutional investors. Comparatively, 0.7% of Aeterna Zentaris shares are held by institutional investors. 0.2% of 180 Life Sciences shares are held by insiders. Comparatively, 0.1% of Aeterna Zentaris shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.
Summary
Aeterna Zentaris beats 180 Life Sciences on 7 of the 11 factors compared between the two stocks.
Get 180 Life Sciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for ATNF and its competitors with MarketBeat's FREE daily newsletter.
New MarketBeat Followers Over Time
This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Media Sentiment Over Time
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
180 Life Sciences Competitors List
Related Companies and Tools
This page (NASDAQ:ATNF) was last updated on 1/22/2025 by MarketBeat.com Staff
